Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

Blood Adv (2024) 8 (18): 4812–4822.

https://doi.org/10.1182/bloodadvances.2023012497

Published: 2024

Includes: Supplemental data

Journal Articles

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Tania Jain, Noel Estrada-Merly, M. Queralt Salas, Soyoung Kim, Jakob DeVos, Min Chen, Xi Fang, Rajat Kumar, Marcio Andrade-Campos, Hany Elmariah, Vaibhav Agrawal, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Amer Beitinjaneh, Vijaya Raj Bhatt, Christopher Bredeson, Zachariah DeFilipp, Bhagirathbhai Dholaria, Nosha Farhadfar, Shatha Farhan, Arpita P. Gandhi, Siddhartha Ganguly, Usama Gergis, Michael R. Grunwald, Nada Hamad, Betty K. Hamilton, Yoshihiro Inamoto, Madiha Iqbal, Omer Jamy, Mark Juckett, Mohamed A. Kharfan-Dabaja, Maxwell M. Krem, Deepesh P. Lad, Jane Liesveld, Monzr M. Al Malki, Adriana K. Malone, Hemant S. Murthy, Guillermo Ortí, Sagar S. Patel, Attaphol Pawarode, Miguel-Angel Perales, Marjolein van der Poel, Olle Ringden, David A. Rizzieri, Alicia Rovó, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Celalettin Ustun, Leo F. Verdonck, John R. Wingard, Baldeep Wirk, Nelli Bejanyan, Richard J. Jones, Taiga Nishihori, Betul Oran, Ryotaro Nakamura, Bart Scott, Wael Saber, Vikas Gupta

Blood Adv (2024) 8 (16): 4281–4293.

https://doi.org/10.1182/bloodadvances.2024013451

Published: 2024

Includes: Supplemental data

Journal Articles

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

Blood Adv (2024) 8 (13): 3488–3496.

https://doi.org/10.1182/bloodadvances.2024012561

Published: 2024

Includes: Supplemental data

Journal Articles

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Blood Adv (2024) 8 (12): 3284–3292.

https://doi.org/10.1182/bloodadvances.2023011049

Published: 2024

Includes: Supplemental data

Journal Articles

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Blood Adv (2024) 8 (8): 2047–2057.

https://doi.org/10.1182/bloodadvances.2023012091

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Blood Adv (2023) 7 (17): 5189–5198.

https://doi.org/10.1182/bloodadvances.2023009853

Published: 2023

Includes: Supplemental data

Journal Articles

The utility of biomarkers in acute GVHD prognostication

Blood Adv (2023) 7 (17): 5152–5155.

https://doi.org/10.1182/bloodadvances.2023009929

Published: 2023

Includes: Supplemental data

Journal Articles

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Blood Adv (2023) 7 (16): 4479–4491.

https://doi.org/10.1182/bloodadvances.2023009885

Published: 2023

Includes: Supplemental data

Journal Articles

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Roni Tamari, Donal P. McLornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernández-Boluda, Sergio Giralt, Jeanne Palmer, Robert Peter Gale, Zachariah DeFilipp, David I. Marks, Marjolein van der Poel, Leo F. Verdonck, Minoo Battiwalla, Miguel Angel Diaz, Vikas Gupta, Haris Ali, Mark Robert Litzow, Hillard M. Lazarus, Usama Gergis, Asad Bashey, Jane Liesveld, Shahrukh Hashmi, Jeffrey J. Pu, Amer Beitinjaneh, Christopher Bredeson, David Rizzieri, Bipin N. Savani, Muhammad Bilal Abid, Siddhartha Ganguly, Vaibhav Agrawal, Vera Ulrike Bacher, Baldeep Wirk, Tania Jain, Corey Cutler, Mahmoud Aljurf, Tamila Kindwall-Keller, Mohamed A. Kharfan-Dabaja, Gerhard C. Hildebrandt, Attaphol Pawarode, Melhem M. Solh, Jean A. Yared, Michael R. Grunwald, Sunita Nathan, Taiga Nishihori, Sachiko Seo, Bart L. Scott, Ryotaro Nakamura, Betul Oran, Tomasz Czerw, Ibrahim Yakoub-Agha, Wael Saber

Blood Adv (2023) 7 (15): 3993–4002.

https://doi.org/10.1182/bloodadvances.2023009886

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Blood Adv (2022) 6 (17): 4936–4948.

https://doi.org/10.1182/bloodadvances.2022007597

Published: 2022

Includes: Supplemental data

Journal Articles

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

Monzr M. Al Malki, Joycelynne Palmer, Ni-Chun Tsai, Sally Mokhtari, Susanta Hui, Weimin Tsai, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Thai Cao, Mathew Mei, Karamjeet S. Sandhu, Tanya Siddiqi, Stephen J. Forman, Ryotaro Nakamura, Guido Marcucci, Anthony Stein, Jeffrey Y. C. Wong, Joseph Rosenthal

Blood Adv (2022) 6 (14): 4098–4106.

https://doi.org/10.1182/bloodadvances.2022007264

Published: 2022

Includes: Supplemental data

Journal Articles

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

Hoda Pourhassan, Corinna La Rosa, Flavia Chiuppesi, Alfredo Puing, Ibrahim Aldoss, Yoonsuh Park, Qiao Zhou, Veronica Karpinski, Katelyn Faircloth, Teodora Kaltcheva, Daisy Johnson, Sandra Ortega Francisco, John A. Zaia, Ryotaro Nakamura, Monzr M. Al Malki, Don J. Diamond, Sanjeet Singh Dadwal, Stephen J. Forman

Blood Adv (2022) 6 (6): 1645–1650.

https://doi.org/10.1182/bloodadvances.2021006282

Published: 2022

Includes: Supplemental data

Journal Articles

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Haris Ali, Ni-Chun Tsai, Timothy Synold, Sally Mokhtari, Weimin Tsia, Joycelynne Palmer, Tracey Stiller, Monzr Al Malki, Ibrahim Aldoss, Amandeep Salhotra, Syed Rahmanuddin, Vinod Pullarkat, Ji-Lian Cai, Anthony Stein, Stephen J. Forman, Guido Marcucci, Matthew Mei, David S. Snyder, Ryotaro Nakamura

Blood Adv (2022) 6 (5): 1444–1453.

https://doi.org/10.1182/bloodadvances.2021005035

Published: 2022

Includes: Supplemental data

Journal Articles

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Monzr M. Al Malki, Ni-Chun Tsai, Joycelynne Palmer, Sally Mokhtari, Weimin Tsai, Thai Cao, Haris Ali, Amandeep Salhotra, Shukaib Arslan, Ibrahim Aldoss, Nicole Karras, Chatchada Karanes, Jasmine Zain, Samer Khaled, Anthony Stein, David Snyder, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura

Blood Adv (2021) 5 (12): 2650–2659.

https://doi.org/10.1182/bloodadvances.2021004192

Published: 2021

Includes: Supplemental data

Journal Articles

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Blood Adv (2021) 5 (10): 2481–2489.

https://doi.org/10.1182/bloodadvances.2020003605

Published: 2021

Includes: Supplemental data

Journal Articles

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Blood Adv (2021) 5 (4): 975–983.

https://doi.org/10.1182/bloodadvances.2020003654

Published: 2021

Journal Articles

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Blood Adv (2020) 4 (24): 6098–6105.

https://doi.org/10.1182/bloodadvances.2020003336

Published: 2020

Includes: Supplemental data

Journal Articles

Comparison of outcomes of HCT in blast phase of BCR-ABL1 − MPN with de novo AML and with AML following MDS

Blood Adv (2020) 4 (19): 4748–4757.

https://doi.org/10.1182/bloodadvances.2020002621

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Zheng Zhou, Rajneesh Nath, Jan Cerny, Hai-Lin Wang, Mei-Jie Zhang, Hisham Abdel-Azim, Vaibhav Agrawal, Gulrayz Ahmed, A. Samer Al-Homsi, Mahmoud Aljurf, Hassan B. Alkhateeb, Amer Assal, Ulrike Bacher, Ashish Bajel, Qaiser Bashir, Minocher Battiwalla, Vijaya Raj Bhatt, Michael Byrne, Jean-Yves Cahn, Mitchell Cairo, Hannah Choe, Edward Copelan, Corey Cutler, Moussab B. Damlaj, Zachariah DeFilipp, Marcos De Lima, Miguel Angel Diaz, Nosha Farhadfar, James Foran, César O. Freytes, Aaron T. Gerds, Usama Gergis, Michael R. Grunwald, Zartash Gul, Mehdi Hamadani, Shahrukh Hashmi, Mark Hertzberg, Gerhard C. Hildebrandt, Nasheed Hossain, Yoshihiro Inamoto, Luis Isola, Tania Jain, Rammurti T. Kamble, Muhammad Waqas Khan, Mohamed A. Kharfan-Dabaja, Partow Kebriaei, Natasha Kekre, Nandita Khera, Hillard M. Lazarus, Jane L. Liesveld, Mark Litzow, Hongtao Liu, David I. Marks, Rodrigo Martino, Vikram Mathews, Asmita Mishra, Hemant S. Murthy, Arnon Nagler, Ryotaro Nakamura, Sunita Nathan, Taiga Nishihori, Rebecca Olin, Richard F. Olsson, Neil Palmisiano, Sagar S. Patel, Mrinal M. Patnaik, Attaphol Pawarode, Miguel-Angel Perales, Ioannis Politikos, Uday Popat, David Rizzieri, Brenda M. Sandmaier, Bipin N. Savani, Sachiko Seo, Nirav N. Shah, Geoffrey L. Uy, David Valcárcel, Leo F. Verdonck, Edmund K. Waller, Youjin Wang, Daniel Weisdorf, Baldeep Wirk, Eric Wong, Jean A. Yared, Wael Saber

Blood Adv (2020) 4 (13): 3180–3190.

https://doi.org/10.1182/bloodadvances.2019001266

Published: 2020

Includes: Supplemental data

Journal Articles

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

Blood Adv (2020) 4 (9): 2073–2083.

https://doi.org/10.1182/bloodadvances.2020001499

Published: 2020

Includes: Supplemental data

NARROW

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

The utility of biomarkers in acute GVHD prognostication

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Comparison of outcomes of HCT in blast phase of BCR-ABL1 − MPN with de novo AML and with AML following MDS

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only